ViAqua Therapeutics was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. One of the major challenges facing the shift to sustainable aquaculture practice is the prevention and treatment of disease. With the annual loss from disease reaching nearly 20% of revenues, there is an acute need for development and introduction of new technologies.
Current treatments depend primarily on antibiotics or non-specific chemicals that may have deleterious environmental effects. Many state of the art treatments, such as vaccines, are still administered by injection, a costly at best or non-feasible administration route for crustaceans’ and some fish species.
ViAqua is developing a biotechnology-based, oral delivery platform for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.
Shai Ufaz, Ph.D.
CEO & Co-Founder
Shai Einbinder, Ph.D.
Congratulations to our World Economic Forum Technology Pioneers 2020
Sanjeev Krishnan, S2G Ventures Managing Director and CIO, will ...Connecting Technology and Business to Create Healthy, Resilient Food Systems.
IN THE NEWS
ViAqua gets $4.3 million investment from S2G Ventures and Thai Union for shrimp health platform
S2G Ventures, Thai Union and Agriline have invested $4.3 million in ViAqua Therapeutics to help develop its RNA-based shrimp health platform and bring other health and nutrition projects closer to commercialisation.
The Fish Site